Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors

Journal of Medicinal Chemistry

Volumn 42, Issue 26, 1999, Pages 5369-5389

  Hennequin, Laurent F ^a   Thomas, Andrew P ^a   Johnstone, Craig ^a   Stokes, Elaine S E ^a   Plé, Patrick A ^a   Lohmann, Jean Jacques M ^a   Ogilvie, Donald J ^a   Dukes, Mike ^a   Wedge, Steve R ^a   Curwen, Jon O ^a   Kendrew, Jane ^a   Lambert Van Der Brempt, Christine ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL AVAILABILITY; CELL DIVISION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; ORGAN SIZE; QUINAZOLINES; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; UTERUS;

EID: 17544387877     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990345w     Document Type: Article

References (79)

1. Fan, T. P. D.; Jaggar, R.; Bicknell, R., Controlling the vasculature: angiogenesis, anti-angiogenesis, and vascular targeting of gene therapy. Trends Pharmacol. Sci. 1995, 16, 57-66.
2. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1995, 1, 27-31.
3. Cullinan-Bove, K.; Koos, R. D. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology 1993, 133, 829-837.
4. Senger, D. R.; Van De Water, L.; Brown, L. F.; Nagy, J. A.; Yeo, K. T.; Yeo, T. K.; Berse, B.; Jackman, R. W.; Dvorak, A. M.; Dvorak, H. F. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer and Metastasis Reviews 1993, 12, 303-324.
5. Hananhan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
6. Jakeman, L. B.; Armanmi, M.; Phillips, H. S.; Ferrara, N. Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 1993, 133, 848-859.
7. Connolly, D. T.; Olander, J. V.; Heuvelman, D.; Nelson, R.; Monsell, R.; Siegel, N.; Haymore, B. L.; Leimgruber, R.; Feder, J. Human vascular permeability factor. Isolation from U937 cells. J. Biol. Chem. 1989, 264, 20017-20024.
8. Plowman, G. D.; Ullrich, A.; Shawver, L. K. Receptor tyrosine kinases as targets for drug intervention. Drug News Perspect. 1994, 7, 334-339.
9. Straw, L. M.; Shawver, L. K. Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Exp. Opin. Invest. Drugs 1998, 7, 553-573.
10. Shawver, L. K.; Lipson, K. E.; Fang, T. A. T.; McMahon, G.; Plowman, G. D.; Strawn, L. M. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discov. Today 1997, 2, 50-63.
11. Tsai, J.-C.; Goldman C. K.; Gillespie, G. Y. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J. Neurosurg. 1995, 82, 864-873.
12. Claffey, K. P.; Brown, L. F.; Del Aguila, L. F.; Tognazzi, K.; Manseau, E. J.; Dvorak, H. F. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumour growth, angiogenesis, and experimental metastasis. Cancer Res. 1996, 56, 172-181.
13. Anan, K.; Morosaki, T.; Katano, M. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 1996, 119, 333-339.
14. Yoshiji H.; Gomez D. E.; Shibuya, M.; Thorgeirsson, U. P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 1996, 56, 2013-2016.
15. Brown, L. F.; Berse, B.; Jackman, R. W.; Tognazzi, K.; Manseau, E. J.; Senger, D. R.; Dvorak, H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993, 53, 4727-4735.
16. Takahashi, Y.; Kitadai, Y.; Bucana, C. D.; Cleary, K. R.; Ellis, L. M. Expression of vascular endothelial growth factor and its receptor, KDR correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995, 55, 3964-3968.
17. Takahashi, A.; Sasaki, H.; Kim, S. J.; Tobisu, K.-I.; Kakizoe, T.; Tsukamoto, T.; Kumamoto, Y.; Sugimura, T.; Terada, M. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994, 54, 4233-4237.
18. Ullrich, A.; Schlessinger J. Signal transduction by receptor tyrosine kinase activity. Cell 1990, 61, 203-212.
19. Halaban, K. Growth factors and tyrosine protein kinases in normal and Malignant Melanocytes. Cancer Met. Rev. 1991, 10, 129-140.
20. Bishop, J. M. The Molecular genetic of cancer. Science 1987, 335, 305-311.
21. De Vries, C.; Escobedo, J. A.; Ueno, H.; Houck, K.; Ferrara, N.; Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255, 989-991.
22. Terman, B. I.; Dougher-Vermazen, M.; Carrion, M. E.; Dimitrov, D.; Armellino, D. C.; Gospodarowicz, D.; Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Comm. 1992, 187, 1579-1586.
23. Kim, K. L.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993, 362, 841-844.
24. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth P.; McMahon G.; Tang, C. Synthesis and Biological Evaluation of 3-substituted Indolin-2-ones: ANovel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor tyrosine Kinases. J. Med. Chem. 1998, 41, 2588-2603.
25. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 267-276.
26. Althuis, T. H.; Hess, H. J. Synthesis and Identification of the Major Metabolites of Prazosin in dog and Rat. J. Med. Chem. 1977, 20, 146-149.
27. Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D.; Sun, L. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1996, 4, 918-928.
28. Zeneca, unpublished data.
29. (a) Lohmann, J.-J., M.; Hennequin, L. F. A.; Thomas, A. P. Preparation and antiangiogenic and/or vascular permeability reducing effect of quinazoline derivatives. WO 9722596 A1 970626. CA:127:135808.
30. (b) Thomas, A. P.; Hennequin, L. F. A.; Ple, P. A. Quinoline derivatives inhibiting the effect of growth factors such as VEGF. WO 9813350 A1 980402. CA:128:270546.
31. (c) Thomas, A. P.; Hennequin, L. F. A.; Johnstone, C.; Stokes, E. S. E.; Lohmann, J.-J., M.; Clayton, E. Preparation of quinazoline derivatives and pharmaceuticals compositions containing them. WO 9813354 A1 980402. CA: 128:257441.
32. (d) Thomas, A. P.; Hennequin, L. F. A. Preparation of anilinocinnolines and related compounds as inhibitors of angiogenesis and vascular permeability. WO 9734876 A1 970925. CA: 127:307392.
33. (e) Thomas, A. P.; Hennequin, L. F. A.; Johnstone C. Preparation of 4-anilinoquinazolines for use in the treatment of disease states associated with antiangiogenesis and/or increased vascular permeability. WO 9732856 A1 970912. CA:127:278209.
34. (f) Thomas, A. P.; Johnstone, C.; Hennequin, L. F. A. Preparation of quinazolines as VEGF inhibitors. WO 9730035 A1 970821. CA:127:262698.
35. Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48(4), 659-666.
36. Rewcastle, G. W.; Denny, W. A., Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenyl-methyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3482-3487.
37. Woodburn, A. J.; Barker, A. J.; Gibson, K. H.; Ashton, S. E.; Wakeling, A. E.; Curry, B. J.; Scarlett, L.; Henthorn, L. R. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical trial development. Proc. Am. Assoc. Cancer Res. 1997, 38, 6633 (Abstract 4251).
38. Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Barker, A. J.; Brown, D. S. Epidermal Growth Factor Receptor Tyrosine Kinase, Structure-Activity Relationship, and antitumour Activity of Novel Quinazolines. Biol. Med. Chem. Lett. 1997, 7, 2723-2728.
39. Iwata, K.; Miller, P. E.; Barbacci, E. G.; Arnold, L.; Doty, J.; DiOrio, C. I.; Pustilnik, L. R.; Reynolds, M.; Theleman, A.; sloan, D.; Moyer, J. D. CP-358,774: a selective EGFR kinase inhibitor with potent antiproliferative activity against HN5 head and neck tumor cells. Proc. Am. Assoc. Cancer Res. 1997, 38, 6633 (Abstract 4248).
40. Lamers, M. B. A. C.; Antson, A. A.; Hubbard, E. E.; Scott, R. K.; Williams, D. H. Structure of the protein tyrosine kinase domain of the C-terminal Src (CSK) in complex with Staurosporine. J. Mol Biol. 1999, 285, 713-725.
41. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; Vesely, J.; Kim, S. H. Multiple Modes of Ligand Recognition: Crystal Structures of Cyclin-Dependent Protein Kinase 2 in Complex with ATP and Two Inhibitors, Olomoucine and Isopentenyladenine. Proteins: Struct., Funct., Genet. 1995, 22, 378-391.
42. Schulze-Gahmen, U.; De Bondt, H. L.; Kim, S. H. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. J. Med. Chem. 1996, 39, 4540-4546.
43. Filgueira de Azevado, Jr., W.; Mueller-Dieckmann, H.-J.; Schulze-Gahman, U.; Worland, P. J.; Sausville, E.; Kim, S.-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2735-2740.
44. Lawrie, A. M.; Noble, M. E. M.; Tunnah, P.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nature Struct. Biol. 1997, 4(9), 796-800.
45. Engh, R. A.; Girod, A.; Kinzel, V.; Huber R.; Bossemeyer, D. Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. J. Biol. Chem. 1996, 271(42), 26157-26164.
46. Prade, L.; Engh, R. A.; Girod, A.; Kinzel, V.; Huber R.; Bossemeyer, D. Staurosporine-induced conformational changes of the cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure 1997, 5(12), 1627-1637.
47. Hubbard, S. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analogue. EMBO J. 1997, 16, 5572-5581.
48. Sicheri, F.; Moarefi, I.; Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997, 385, 602-609.
49. Mohamadi, M.; McMahon, G.; Sun, L. T.; Tang, C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276, 955-960.
50. Mohamadi, M.; Froum, S.; Hamby, J. M.; Schroeder, M. C.; Panek, R. L.; Lu, G. H.; Eliseenkova, A. V.; Green, D.; Schlessinger, J.; Hubbard, S. R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998, 17(20), 5896-5904.
51. Tong, L.; Pav, S.; White, D. M.; Rogers, S.; Crane, K. M.; Cywin, C. L.; Brown, M. L., Pargellis, C. A. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature Struct. Biol. 1997, 4(4), 311-316.
52. Wilson, K. P.; McCaffrey, P. G.; Hsiao, K.; Pazhanisamy, S.; Galullo, V.; Bemis, G. W.; Fitzgibbon, M. J.; Caron, P. R.; Murcko, M. A.; Su, M. S. S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 1997, 4, 423-431.
53. Furet, P.; Caravatti, G.; Priestle, J.; Sowadski, J.; Trinks, U.; Traxler, P. Modeling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52 411. J. Comput.-Aided Mol. Des. 1995, 9, 465-472.
54. Traxler, P. M.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, T.; Lydon, N. 4-(phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1996, 39, 2285-2292
55. Traxler, P. M.; Bold, G.; Frei, J.; Lang, M.; Lydon, N.; Mett, H.; Buchdunger, E.; Meyer, T.; Mueller, M.; Furet, P. Use of a Pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J. Med. Chem. 1997, 40, 3601-3616.
56. Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M..; Showalter, H. D. H.; Denny, W. A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. J. Med. Chem. 1997, 40, 1519-1529.
57. Trumpp-Kallmeyer, S.; Rubin, J. R.; Humblet, C.; Hamby, J. M.; Showalter, H. D. H. Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido[2,3-d]pyrimidine Inhibitors. J. Med. Chem. 1998, 41, 1752-1763.
58. Zheng, J.; Trafny, E. A.; Knighton, D. R.; Xuong, N.-H.; Taylor, S. S.; Ten Eyck, L. F.; Sowadsky, J. M. 2.2 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr. 1993, D49, 362-365.
59. (a) Ogilvie, D. J.; Wedge, S. R.; Dukes, M.; Kendrew, J.; Curwen, J. O.; Thomas, A. P.; Hennequin, L. F.; Plé, P.; Stokes, E. S. E.; Johnstone, C.; Wadsworth, P.; Richmond, G. H. P.; Curry, B. ZD4190: An orally administered inhibitor of VEGF signaling with pan-xenograft anti-tumour activity. AACR Philadelphia 1999 Abstract 458.
60. (b) Wedge, S. R.; Waterton, J. C.; Tessier, J. J.; Checkley, D.; Dukes, M.; Kendrew, J.; Curry, B. Effect of the VEGF receptor tyrosine kinase inhibitor ZD4190 on vascular endothelial permeability. AACR Philadelphia 1999 Abstract 2741. (To be published).
61. De Bondt, H. L.; Rosenblatt, J.; Jancarik, J.; Jones, H. D.; Morgan, D. O.; Kim, S. H. Crystal structure of cyclin-dependent kinase 2. Nature 1993, 363, 595-602.
62. Zang, F.; Strand, A.; Robbins, D.; Cobb, M. H.; Goldsmith, E. J. Atomic structure of the MAP kinase ERK2 at 2.3 A resolution. Nature 1994, 367, 704-711.
63. Owen, D. J.; Noble, M. E. M.; Garman, E. F.; Papageorgiou, A. C.; Johnson, L. N. Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product. Structure 1995, 3, 467-482.
64. Xu, R. M.; Carmel, G.; Sweet, R. M.; Kuret, J.; Cheng, X. Crystal structure of casein kinase-1, a phosphate-directed protein kinase. EMBO J. 1995, 14, 1015-1023.
65. (a) Hanks, S. K.; Quinn, A. M.; Hunter, T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241, 42-52.
66. (b) Hanks, S. K.; Quinn, A. M. Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members. Methods Enzymol. 1991, 200, 38-62.
67. Zheng, J.; Knighton, D. R.; Xuong, N.-H.; Taylor, S. S.; Sowadsky, J. M.; Ten Eyck, L. F. Crystal structures of the myristylated catalytic subunit of cAMP-dependent protein kinase reveal open and closed conformations. Protein Sci. 1993, 2, 1559-1573.
68. Knighton, D. R.; Cadena, D. L.; Zheng, J.; Ten Eyck, L. F.; Taylor, S. S.; Sowadski, J. M.; Gill, G. N. Structural features that specify tyrosine kinase activity deduced from homology modeling of the epidermal growth factor receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90(11), 5001-5005.
69. Sali, A.; Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234, 779-815.
70. Quanta; Molecular Simulations, Incorporated, 9685 Scranton Rd, San Diego, CA 92121-3752.
71. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: a program for macromolecular energy, minimisation, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
72. Momany, F. A.; Rone, R. Validation of the general purpose QUANTA3.2/CHARMm force field. J. Comput. Chem. 1992, 13, 888-900.
73. McTigue, M. A.; Wickersham, J. A.; Pinko, C.; Showalter, R. E.; Parast, C. V.; Tempczyk-Russel, A. T.; Gehring, M. R.; Mroczkowski, B.; Kan, C.-C.; Villafranca, J. E.; Appelt, K. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure 1999, 7, 319-330.
74. Adams, R. R.; Whitmore, F. C. Heterocyclic basic compounds. IV. 2-aminoalkylamino-pyrimidines. J. Am. Chem. Soc. 1945, 67, 735-738.
75. Calderon, S. N.; Izenwasser, S.; Heller, B.; Gutkind, J. S.; Mattson, M. V., Su, T.-P.; Newman, A. H. Novel 1-Phenylcycloalkanecarboxylic Acid Derivatives Are Potent and Selective σ1 Ligands. J. Med. Chem. 1994, 37, 2285-2291.
76. 2 Synthetase Inhibition and Bronchodilation. 1. 2-[2-(1-Imidazoryl)alkyl]-1(2H)-phthalazinones. J. Med. Chem. 1993, 36, 4052-4060.
77. Ainsworth, C.; Jones, R. G. Isomeric and Nuclear-substituted β-Aminoethyl-1,2,4-triazoles. J. Am. Chem. Soc. 1955, 77, 621-622.
78. Kume, M.; Kubota, T.; Kunura, Y.; Nakashimizu, H.; Motokawa, K.; Nakano M. Orally Active Cephalosporins II. Synthesis and Structure-Activity Relationships of New 7β-[(Z)-2-(2-Aminothiazol-4-yl)-2-Hydroxyiminoacetamido]-Cephalosporins with 1,2,3-Triazole in C-3 Side Chain. J. Antibio. 1993, 46, 177-195.
79. Goddard, S. J.; Levitt, G. Substituted Isoindoles. US Patent 1978, 4, 120, 693. CA: 90: 38788.